Insurance denials of first attempts to fill prescriptions for brand-name prescription drugs with no generic competitors increased more than two-thirds between 2018 and 2024. While this may help control drug spending, it can also create barriers to timely treatment and place administrative burdens.

Insurance denials of first attempts to fill prescriptions for brand-name prescription drugs with no generic competitors increased more than two-thirds between 2018 and 2024. While this may help control drug spending, it can also create barriers to timely treatment and place administrative burdens.